Invivyd, Inc. (NASDAQ:IVVD) Given Average Recommendation of “Hold” by Analysts

Shares of Invivyd, Inc. (NASDAQ:IVVD) have earned an average recommendation of “Hold” from the six research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $8.00.

IVVD has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Invivyd in a report on Wednesday, April 29th. Wall Street Zen cut Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Invivyd in a research report on Monday, June 15th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Invivyd in a research note on Tuesday.

Invivyd Trading Down 11.9%

NASDAQ IVVD opened at $0.83 on Thursday. Invivyd has a 12 month low of $0.48 and a 12 month high of $3.07. The stock has a market cap of $244.53 million, a price-to-earnings ratio of -2.68 and a beta of 0.67. The company’s 50 day moving average is $1.08 and its two-hundred day moving average is $1.59.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.05). The firm had revenue of $13.74 million during the quarter, compared to the consensus estimate of $18.04 million. Invivyd had a negative return on equity of 53.48% and a negative net margin of 138.90%. Sell-side analysts forecast that Invivyd will post -0.5 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. OMERS ADMINISTRATION Corp grew its holdings in Invivyd by 9.0% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 106,900 shares of the company’s stock valued at $139,000 after buying an additional 8,800 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Invivyd by 54.3% in the first quarter. Bank of New York Mellon Corp now owns 27,184 shares of the company’s stock worth $35,000 after buying an additional 9,568 shares in the last quarter. Courier Capital LLC purchased a new position in shares of Invivyd in the fourth quarter worth $25,000. Bronte Capital Management Pty Ltd. purchased a new position in Invivyd during the fourth quarter valued at $27,000. Finally, DRW Securities LLC purchased a new position in Invivyd during the fourth quarter valued at $27,000. 70.36% of the stock is currently owned by institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.